Repligen Corporation (RGEN)

Repligen's stock has outperformed the S&P 500 by 28.3% over the past six months, achieving a 36.5% gain. Key events impacting the stock price include strong quarterly results in Q2 and Q3 2025, leading to raised full-year 2025 financial guidance. Wall Street Zen upgraded Repligen from "hold" to "buy" in February 2026, with UBS and Barclays also raising price targets. Over the past 90 days (prior to February 7, 2026), company insiders sold 49,657 shares worth approximately $7.72 million, with insiders now owning 1.20% of the stock.

Demand for Repligen's products and services can be influenced by broader industry trends and customer behavior. 2023 was a challenging year for Repligen and the bioprocessing industry as it adjusted to a post-pandemic environment. The second half of 2023 saw improved orders at biopharmaceutical and CDMO accounts, and a strengthening funnel of opportunities, particularly in new modality markets. In Q2 and Q3 2025, Repligen reported healthy demand in consumables and capital equipment, with orders growing over 20% year-over-year. New modalities showed solid performance in 2023, representing 18% of total revenue and adding over 85 new accounts.

Repligen Corporation is a global life sciences company focused on bioprocessing technologies and systems, operating in the healthcare sector. It provides critical components and systems to enhance process efficiency, yield, and product quality for biopharmaceutical companies and CDMOs. Repligen's product portfolio includes Filtration, Chromatography, Process Analytics, and Proteins. These technologies are used throughout the biopharmaceutical manufacturing workflow, serving a wide range of biologics.

Repligen is headquartered in Waltham, Massachusetts, and operates across 22 sites globally, with a significant presence in the United States, Europe, and Asia Pacific. In Q1 2025, North America accounted for 50% of revenue, Europe for 35%, and Asia Pacific (excluding China) for 15%. China's revenue contribution remained small at approximately 2% of total revenue and continued to decline. For the full year 2024, customers in North America, Europe, and Asia Pacific contributed 44%, 37%, and 19% of revenue, respectively.

Repligen has maintained a strong brand reputation, driven by its commitment to innovation, strategic acquisitions, and focus on sustainability. The company continues to launch advanced products, such as the CTech™ SoloVPE® PLUS System and TangenX® SC. Repligen has strategically expanded its portfolio through acquisitions, including Metenova and FlexBiosys Inc. Repligen was named one of the world's greenest companies in 2025 by Newsweek, reflecting its efforts in reducing waste generation.

Repligen Corporation's ownership is predominantly held by institutional investors, reflecting strong confidence in its bioprocessing focus. As of January 2025, institutional investors collectively owned approximately 101.91% of the company's shares, with mutual funds accounting for a substantial 91.68%. Individual and retail investors comprise about 40.15% of the ownership, while insiders hold a smaller stake, ranging from 0.64% to 0.75%. Major institutional shareholders include BlackRock, Inc., Vanguard Group Inc., Price T Rowe Associates Inc /md/, United Capital Financial Advisers, Llc, State Street Corp, Fmr Llc, Citadel Advisors Llc, and Point72 Asset Management, L.P.